- Home
- SLG vs QURE Comparison
SLG vs QURE Comparison
Compare SLG & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | QURE |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLG | QURE |
|---|---|---|
| Price | $50.38 | $21.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $56.21 | ★ $60.37 |
| AVG Volume (30 Days) | 924.3K | ★ 2.4M |
| Earning Date | 10-21-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,003,046,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $54.78 |
| Revenue Next Year | N/A | $356.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.18 | N/A |
| 52 Week Low | $34.77 | $8.73 |
| 52 Week High | $60.09 | $71.50 |
Technical Indicators
Market Signals| Indicator | SLG | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 26.55 |
| Support Level | $48.65 | $20.25 |
| Resistance Level | $53.11 | $25.61 |
| Average True Range (ATR) | 1.97 | 1.07 |
| MACD | 0.52 | 0.75 |
| Stochastic Oscillator | 93.98 | 37.92 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 30.6 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.